Rhinomed Limited (ASX:RNO)

25.5¢

right-arrow Created with Sketch. 0 (0%)
MCAP $66.25M
Last trade 16.10pm 28/01/2022 20mins delayed

Latest Announcements

25/01/2022 Price SensitivePSRNORhinomed Limited
22/12/2021RNORhinomed Limited
22/12/2021RNORhinomed Limited
135
MCap
22/12/2021RNORhinomed Limited
130
MCap
21/12/2021 Price SensitivePSRNORhinomed Limited
20/12/2021RNORhinomed Limited
20/12/2021RNORhinomed Limited
20/12/2021RNORhinomed Limited

Company Overview

Rhinomed Limited is an Australia-based medical technology company that enhancing respiration, sleep, diagnosis of upper respiratory disease, and nasal drug delivery. The Company’s products include Mute, Turbine, Pronto Sleep, and Pronto Clear. The Mute is a nasal technology that is designed to allow the user to manage the sleep by breathing more and snoring less. The Turbine is a nasal dilator designed to assist the user to breathe during aerobic exercise. Pronto Sleep, which combines the benefits of a nasal dilator, to open the nose and improve airflow, with the soothing vapors of four pure essential oils. Pronto Clear, which combines the benefits of a nasal dilator, to open the nose and improve airflow, with the ability to deliver the vapors of six pure essential oils traditionally known to clear a stuffy nose naturally. Its products, including Turbine and Mute, are sold online and through pharmacies, sleep clinics, and sports stores.

RNO in the news

Rhinomed’s (RNO) interim results for its trial on respiratory virus diagnosis reveal…
Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to…
Rhinomed (RNO) receives an order for one million Rhinoswabs from the Victorian…
Rhinomed (RNO) receives a purchase order from the NSW Government for its…

Search Previous Announcements